UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2025

Revenue DeclineResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹22.00

prior close

₹22.25

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%-2.5% vs market

Pharmaceuticals peers, median of 159sector+0.4%-1.9% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.7

10m

-4.7

15m

-4.7

30m

-4.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+1.0-2.5+0.4-1.9

Next day

-0.3+0.5-0.8+0.3-0.5

+2.3-0.0+2.3-0.0+2.3

+0.0-1.5+1.5-1.2+1.2

+0.0-2.2+2.2-1.8+1.8

+0.0-1.2+1.2-1.8+1.8

-1.1-2.4+1.2-2.6+1.5

15d

-14.9-8.8-6.0-6.9-7.9

-9.0-8.3-0.7-5.1-3.9

+10.5-3.5+14.1-3.5+14.1

-8.8+6.4-15.2+3.2-12.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beryl Drugs Ltd reported Q3 FY26 (quarter ended 31 Dec 2025) revenue from operations of about ₹3.78 crore, down sharply from ₹5.51 crore in the same quarter last year (around 31% YoY decline). Profit after tax for the quarter stood at roughly ₹5.22 lakh versus ₹12.70 lakh in Q3 FY25, a decline of nearly 59% YoY. For the nine months ended Dec 2025, revenue was ₹15.69 crore vs ₹17.17 crore in the same period last year. The weakness is linked to a part of the company's manufacturing facility being under suspension since 11 Feb 2025 following FDA directions; the suspension was lifted on 28 Nov 2025, allowing operations to resume in that section.

Likely market impact

Short-term: Weak quarter with sharp revenue and profit decline as the suspended facility hurt production for most of the period. Medium-term: Resumption of operations from late Nov 2025 should help revenue and margins recover in coming quarters, but investors should watch whether full normalcy is restored.